Company Profile

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Employees

Sector

Biotechnology & Medical Research

More about the company

19-01-08	GlaxoSmithKline : to look for early-stage assets - CEO	RE
18-12-03	Relief rally boosts Wall Street on U.S.-China trade truce	RE
18-12-03	U.S.-China trade truce triggers European share surge	RE
18-12-03	GSK slows down UK stocks after China-U.S. trade truce	RE
18-12-03	Merck and : GSK slides after buying cancer firm Tesaro for hefty $5.1 billion	RE
18-12-03	Unilever swallows GSK's Indian Horlicks business for $3.8 billion	RE
18-06-27	AstraZeneca : Merck eye $1 billion boost from cancer drug success	RE
17-10-19	China biotech's 'coming out party' masks long road ahead	RE
17-08-17	AstraZeneca : FDA expands use of AstraZeneca/Merck ovarian cancer drug	RE
17-03-14	AstraZeneca : ovarian cancer drug slows disease markedly in study	RE
17-02-08	Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources	RE
16-06-29	TESARO : Wall Street rebounds from Brexit with second day of big gains	RE
14-06-26	AbbVie : Cancer drug setback tarnishes AstraZeneca's R&D claims	RE

19-01-08	WEDNESDAY DEADLINE REMINDER: The Schall Law Firm Announces It is Investigating Claims against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm	BU
19-01-07	DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm	BU
18-12-21	Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro, Inc. of Class Action Lawsuit and Upcoming Deadline - TSRO	PR
18-12-04	Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Tesaro, Inc. - TSRO	PR
18-12-04	TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes	GL

18-12-19	GSK va contrôler la santé grand public de Pfizer et se scinder
18-12-03	Dow Jones Industrial Average : Wall Street salue la trêve commerciale USA-Chine
18-12-03	Point marchés-Wall Street salue la trêve commerciale USA-Chine (actualisé)
18-12-03	TESARO : GSK va racheter la biotech Tesaro pour 5,1 milliards de dollars
18-12-03	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street

Director	Title	Age	Since
Mary Lynne Hedley BRD	Director/Board Member	63	2010-03-25
Arnold Lewis Oronsky BRD	Director/Board Member	85	2011-05-31
James Armitage BRD	Director/Board Member	79	2013-05-08

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TESARO INC	+0.03%	+0.40%	-	-	0
ARGENX SE	-0.03%	+0.40%	+57.52%	+108.61%	54.92B
WUXI APPTEC CO., LTD.	-0.34%	+3.51%	+45.55%	+40.16%	44.31B
BIONTECH SE	+0.29%	+6.20%	-14.80%	-19.65%	22.96B
INSMED INCORPORATED	-0.40%	+3.49%	-1.29%	+387.06%	21.12B
WUXI BIOLOGICS (CAYMAN) INC.	-3.30%	0.00%	+12.98%	-36.90%	16.31B
GENMAB A/S	-1.24%	-1.83%	+7.22%	-40.94%	15.19B
EXELIXIS, INC.	-0.24%	+2.44%	+27.43%	+177.49%	13.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.91%	+9.19%	+18.62%	-	12.48B
PHARMAESSENTIA CORPORATION	+0.32%	+2.81%	+96.37%	+213.49%	11.21B
Average	-0.38%	+2.75%	+27.74%	+103.66%	23.54B
Weighted average by Cap.	-0.36%	+2.86%	+32.15%	+95.33%

TESARO Inc Stock

Stocks

US8815691071

Biotechnology & Medical Research

Latest news : TESARO Inc

Press Releases: TESARO Inc

News in other languages: TESARO Inc

Quotes and Performance

Managers and Directors: TESARO Inc

Bio Therapeutic Drugs

Company Profile